Epigenetics in human gliomas

Cancer Letters

Volumn 342, Issue 2, 2014, Pages 185-192

  Kreth, Simone ^a   Thon, Niklas ^a   Kreth, Friedrich W ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Epigenetic networks; Glioblastoma; MicroRNAs; Stereotactic biopsy

Indexed keywords

BUTYRIC ACID; DNA; HISTONE DEACETYLASE INHIBITOR; MICRORNA; TEMOZOLOMIDE; VALPROIC ACID; VORINOSTAT;

CANCER GRADING; CANCER PROGNOSIS; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; GENE EXPRESSION; GENETIC REGULATION; GENOME ANALYSIS; GLIOBLASTOMA; GLIOMA; HISTONE MODIFICATION; HUMAN; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SHORT SURVEY; TRANSCRIPTOMICS; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

EID: 84888204856     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.04.008     Document Type: Review

References (135)

1. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-466.
2. Westphal M., Lamszus K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat. Rev. Neurosci. 2011, 12:495-508.
3. Kreth F.W., Faist M., Grau S., Ostertag C.B. Interstitial 125I radiosurgery of supratentorial de novo WHO Grade 2 astrocytoma and oligoastrocytoma in adults: long-term results and prognostic factors. Cancer 2006, 106:1372-1381.
4. Ohgaki H., Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009, 100:2235-2241.
5. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
6. Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., Pan F., Pelloski C.E., Sulman E.P., Bhat K.P., Verhaak R.G., Hoadley K.A., Hayes D.N., Perou C.M., Schmidt H.K., Ding L., Wilson R.K., Van Den Berg D., Shen H., Bengtsson H., Neuvial P., Cope L.M., Buckley J., Herman J.G., Baylin S.B., Laird P.W., Aldape K. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522.
7. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
8. Berdasco M., Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev. Cell 2010, 19:698-711.
9. Portela A., Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol. 2010, 28:1057-1068.
10. Martinez R., Schackert G. Epigenetic aberrations in malignant gliomas: an open door leading to better understanding and treatment. Epigenetics 2007, 2:147-150.
11. Suzuki M.M., Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 2008, 9:465-476.
12. Irizarry R.A., Ladd-Acosta C., Wen B., Wu Z., Montano C., Onyango P., Cui H., Gabo K., Rongione M., Webster M., Ji H., Potash J.B., Sabunciyan S., Feinberg A.P. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 2009, 41:178-186.
13. Chen Z.X., Riggs A.D. DNA methylation and demethylation in mammals. J. Biol. Chem. 2011, 286:18347-18353.
14. Hellman A., Chess A. Gene body-specific methylation on the active X chromosome. Science 2007, 315:1141-1143.
15. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8:286-298.
16. Robertson K.D. DNA methylation and human disease. Nat. Rev. Genet. 2005, 6:597-610.
17. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61:3225-3229.
18. Cadieux B., Ching T.T., Vandenberg S.R., Costello J.F. Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res. 2006, 66:8469-8476.
19. Martinez R., Martin-Subero J.I., Rohde V., Kirsch M., Alaminos M., Fernandez A.F., Ropero S., Schackert G., Esteller M. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 2009, 4:255-264.
20. Wu X., Rauch T.A., Zhong X., Bennett W.P., Latif F., Krex D., Pfeifer G.P. CpG island hypermethylation in human astrocytomas. Cancer Res. 2010, 70:2718-2727.
21. Agnihotri S., Wolf A., Munoz D.M., Smith C.J., Gajadhar A., Restrepo A., Clarke I.D., Fuller G.N., Kesari S., Dirks P.B., McGlade C.J., Stanford W.L., Aldape K., Mischel P.S., Hawkins C., Guha A. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. J. Exp. Med. 2011, 208:689-702.
22. Tepel M., Roerig P., Wolter M., Gutmann D.H., Perry A., Reifenberger G., Riemenschneider M.J. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int. J. Cancer 2008, 123:2080-2086.
23. Nakamura M., Watanabe T., Yonekawa Y., Kleihues P., Ohgaki H. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C→A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 2001, 22:1715-1719.
24. Nakamura M., Watanabe T., Klangby U., Asker C., Wiman K., Yonekawa Y., Kleihues P., Ohgaki H. P14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol. 2001, 11:159-168.
25. Stone A.R., Bobo W., Brat D.J., Devi N.S., Van Meir E.G., Vertino P.M. Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am. J. Pathol. 2004, 165:1151-1161.
26. Kosla K., Pluciennik E., Kurzyk A., Jesionek-Kupnicka D., Kordek R., Potemski P., Bednarek A.K. Molecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiforme. J. Neurooncol. 2011, 101:207-213.
27. Waha A., Guntner S., Huang T.H., Yan P.S., Arslan B., Pietsch T., Wiestler O.D., Waha A. Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia 2005, 7:193-199.
28. Lindemann C., Hackmann O., Delic S., Schmidt N., Reifenberger G., Riemenschneider M.J. SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation. Acta Neuropathol. 2011, 122:241-251.
29. Alonso M.M., Diez-Valle R., Manterola L., Rubio A., Liu D., Cortes-Santiago N., Urquiza L., Jauregi P., de Munain A.L., Sampron N., Aramburu A., Tejada-Solis S., Vicente C., Odero M.D., Bandres E., Garcia-Foncillas J., Idoate M.A., Lang F.F., Fueyo J., Gomez-Manzano C. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One 2011, 6:e26740.
30. Uhlmann K., Rohde K., Zeller C., Szymas J., Vogel S., Marczinek K., Thiel G., Nurnberg P., Laird P.W. Distinct methylation profiles of glioma subtypes. Int. J. Cancer 2003, 106:52-59.
31. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., Alexe G., Lawrence M., O'Kelly M., Tamayo P., Weir B.A., Gabriel S., Winckler W., Gupta S., Jakkula L., Feiler H.S., Hodgson J.G., James C.D., Sarkaria J.N., Brennan C., Kahn A., Spellman P.T., Wilson R.K., Speed T.P., Gray J.W., Meyerson M., Getz G., Perou C.M., Hayes D.N. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
32. Lu C., Ward P.S., Kapoor G.S., Rohle D., Turcan S., Abdel-Wahab O., Edwards C.R., Khanin R., Figueroa M.E., Melnick A., Wellen K.E., O'Rourke D.M., Berger S.L., Chan T.A., Levine R.L., Mellinghoff I.K., Thompson C.B. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
33. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010, 465:966.
34. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., Ito S., Yang C., Wang P., Xiao M.T., Liu L.X., Jiang W.Q., Liu J., Zhang J.Y., Wang B., Frye S., Zhang Y., Xu Y.H., Lei Q.Y., Guan K.L., Zhao S.M., Xiong Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
35. Guo J.U., Su Y., Zhong C., Ming G.L., Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011, 145:423-434.
36. Jin S.G., Jiang Y., Qiu R., Rauch T.A., Wang Y., Schackert G., Krex D., Lu Q., Pfeifer G.P. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res. 2011, 71:7360-7365.
37. T.F. Kraus, D. Globisch, M. Wagner, S. Eigenbrod, D. Widmann, M. Munzel, M. Muller, T. Pfaffeneder, B. Hackner, W. Feiden, U. Schuller, T. Carell, H.A. Kretzschmar, Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base," are associated with anaplasia in human brain tumors, Int. J. Cancer (2012), [Epub ahead of print]. http://dx.doi.org/10.1002/ijc.27429.
38. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H.F., Tallman M.S., Sun Z., Wolniak K., Peeters J.K., Liu W., Choe S.E., Fantin V.R., Paietta E., Lowenberg B., Licht J.D., Godley L.A., Delwel R., Valk P.J., Thompson C.B., Levine R.L., Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
39. Williams K., Christensen J., Pedersen M.T., Johansen J.V., Cloos P.A., Rappsilber J., Helin K. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011, 473:343-348.
40. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de T.N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997-1003.
41. Thon N., Eigenbrod S., Kreth S., Lutz J., Tonn J.C., Kretzschmar H., Peraud A., Kreth F.W. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer 2012, 118:452-460.
42. Wick W., Hartmann C., Engel C., Stoffels M., Felsberg J., Stockhammer F., Sabel M.C., Koeppen S., Ketter R., Meyermann R., Rapp M., Meisner C., Kortmann R.D., Pietsch T., Wiestler O.D., Ernemann U., Bamberg M., Reifenberger G., von D.A., Weller M. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 2009, 27:5874-5880.
43. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
44. Kreth S., Thon N., Eigenbrod S., Lutz J., Ledderose C., Egensperger R., Tonn J.C., Kretzschmar H.A., Hinske L.C., Kreth F.W. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One 2011, 6:e17156.
45. Margueron R., Reinberg D. Chromatin structure and the inheritance of epigenetic information. Nat. Rev. Genet. 2010, 11:285-296.
46. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
47. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., Iyer N.G., Perez-Rosado A., Calvo E., Lopez J.A., Cano A., Calasanz M.J., Colomer D., Piris M.A., Ahn N., Imhof A., Caldas C., Jenuwein T., Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
48. Karlic R., Chung H.R., Lasserre J., Vlahovicek K., Vingron M. Histone modification levels are predictive for gene expression. Proc. Natl. Acad. Sci. USA 2010, 107:2926-2931.
49. Bannister A.J., Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011, 21:381-395.
50. Santos-Rosa H., Schneider R., Bannister A.J., Sherriff J., Bernstein B.E., Emre N.C., Schreiber S.L., Mellor J., Kouzarides T. Active genes are tri-methylated at K4 of histone H3. Nature 2002, 419:407-411.
51. Campos B., Bermejo J.L., Han L., Felsberg J., Ahmadi R., Grabe N., Reifenberger G., Unterberg A., Herold-Mende C. Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Sci. 2011, 102:387-392.
52. Lucio-Eterovic A.K., Cortez M.A., Valera E.T., Motta F.J., Queiroz R.G., Machado H.R., Carlotti C.G., Neder L., Scrideli C.A., Tone L.G. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 2008, 8:243.
53. Schmidt N., Windmann S., Reifenberger G., Riemenschneider M.J. DNA hypermethylation and histone modifications downregulate the candidate tumor suppressor gene RRP22 on 22q12 in human gliomas. Brain Pathol. 2012, 22:17-25.
54. Mottet D., Pirotte S., Lamour V., Hagedorn M., Javerzat S., Bikfalvi A., Bellahcene A., Verdin E., Castronovo V. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 2009, 28:243-256.
55. Costa B.M., Smith J.S., Chen Y., Chen J., Phillips H.S., Aldape K.D., Zardo G., Nigro J., James C.D., Fridlyand J., Reis R.M., Costello J.F. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res. 2010, 70:453-462.
56. Costa F.F. Non-coding RNAs, epigenetics and complexity. Gene 2008, 410:9-17.
57. Esteller M. Non-coding RNAs in human disease. Nat. Rev. Genet. 2011, 12:861-874.
58. Lau N.C., Lim L.P., Weinstein E.G., Bartel D.P. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001, 294:858-862.
59. Mendell J.T. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle 2005, 4:1179-1184.
60. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
61. Farh K.K., Grimson A., Jan C., Lewis B.P., Johnston W.K., Lim L.P., Burge C.B., Bartel D.P. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 2005, 310:1817-1821.
62. Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., Bartel D.P., Linsley P.S., Johnson J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
63. John B., Sander C., Marks D.S. Prediction of human microRNA targets. Methods Mol. Biol. 2006, 342:101-113.
64. Gunaratne P.H., Coarfa C., Soibam B., Tandon A. MiRNA data analysis: next-gen sequencing. Methods Mol. Biol. 2012, 822:273-288.
65. Kozomara A., Griffiths-Jones S. MiRBase: integrating microRNA annotation and deep-sequencing data. Nucl. Acids Res. 2011, 39:D152-D157.
66. Selbach M., Schwanhausser B., Thierfelder N., Fang Z., Khanin R., Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455:58-63.
67. Soifer H.S., Rossi J.J., Saetrom P. MicroRNAs in disease and potential therapeutic applications. Mol. Ther. 2007, 15:2070-2079.
68. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10:704-714.
69. P. Carninci, T. Kasukawa, S. Katayama, J. Gough, M.C. Frith, N. Maeda, R. Oyama, T. Ravasi, B. Lenhard, C. Wells, R. Kodzius, K. Shimokawa, V.B. Bajic, S.E. Brenner, S. Batalov, A.R. Forrest, M. Zavolan, M.J. Davis, L.G. Wilming, V. Aidinis, J.E. Allen, A. Ambesi-Impiombato, R. Apweiler, R.N. Aturaliya, T.L. Bailey, M. Bansal, L. Baxter, K.W. Beisel, T. Bersano, H. Bono, A.M. Chalk, K.P. Chiu, V. Choudhary, A. Christoffels, D.R. Clutterbuck, M.L. Crowe, E. Dalla, B.P. Dalrymple, B.B. de, G.G. Della, B.D. di, T. Down, P. Engstrom, M. Fagiolini, G. Faulkner, C.F. Fletcher, T. Fukushima, M. Furuno, S. Futaki, M. Gariboldi, P. Georgii-Hemming, T.R. Gingeras, T. Gojobori, R.E. Green, S. Gustincich, M. Harbers, Y. Hayashi, T.K. Hensch, N. Hirokawa, D. Hill, L. Huminiecki, M. Iacono, K. Ikeo, A. Iwama, T. Ishikawa, M. Jakt, A. Kanapin, M. Katoh, Y. Kawasawa, J. Kelso, H. Kitamura, H. Kitano, G. Kollias, S.P. Krishnan, A. Kruger, S.K. Kummerfeld, I.V. Kurochkin, L.F. Lareau, D. Lazarevic, L. Lipovich, J. Liu, S. Liuni, S. McWilliam, B.M. Madan, M. Madera, L. Marchionni, H. Matsuda, S. Matsuzawa, H. Miki, F. Mignone, S. Miyake, K. Morris, S. Mottagui-Tabar, N. Mulder, N. Nakano, H. Nakauchi, P. Ng, R. Nilsson, S. Nishiguchi, S. Nishikawa, F. Nori, O. Ohara, Y. Okazaki, V. Orlando, K.C. Pang, W.J. Pavan, G. Pavesi, G. Pesole, N. Petrovsky, S. Piazza, J. Reed, J.F. Reid, B.Z. Ring, M. Ringwald, B. Rost, Y. Ruan, S.L. Salzberg, A. Sandelin, C. Schneider, C. Schonbach, K. Sekiguchi, C.A. Semple, S. Seno, L. Sessa, Y. Sheng, Y. Shibata, H. Shimada, K. Shimada, D. Silva, B. Sinclair, S. Sperling, E. Stupka, K. Sugiura, R. Sultana, Y. Takenaka, K. Taki, K. Tammoja, S.L. Tan, S. Tang, M.S. Taylor, J. Tegner, S.A. Teichmann, H.R. Ueda, N.E. van, R. Verardo, C.L. Wei, K. Yagi, H. Yamanishi, E. Zabarovsky, S. Zhu, A. Zimmer, W. Hide, C. Bult, S.M. Grimmond, R.D. Teasdale, E.T. Liu, V. Brusic, J. Quackenbush, C. Wahlestedt, J.S. Mattick, D.A. Hume, C. Kai, D. Sasaki, Y. Tomaru, S. Fukuda, M. Kanamori-Katayama, M. Suzuki, J. Aoki, T. Arakawa, J. Iida, K. Imamura, M. Itoh, T. Kato, H. Kawaji, N. Kawagashira, T. Kawashima, M. Kojima, S. Kondo, H. Konno, K. Nakano, N. Ninomiya, T. Nishio, M. Okada, C. Plessy, K. Shibata, T. Shiraki, S. Suzuki, M. Tagami, K. Waki, A. Watahiki, Y. Okamura-Oho, H. Suzuki, J. Kawai, Y. Hayashizaki, The transcriptional landscape of the mammalian genome, Science 309 (2005) 1559-1563.
70. Lee Y.S., Dutta A. MicroRNAs: small but potent oncogenes or tumor suppressors. Curr. Opin. Invest. Drugs 2006, 7:560-564.
71. Zhang B., Pan X., Cobb G.P., Anderson T.A. MicroRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007, 302:1-12.
72. Calin G.A., Croce C.M. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 2006, 25:6202-6210.
73. Kumar M.S., Lu J., Mercer K.L., Golub T.R., Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 2007, 39:673-677.
74. Lujambio A., Esteller M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 2007, 6:1455-1459.
75. Kim H., Huang W., Jiang X., Pennicooke B., Park P.J., Johnson M.D. Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc. Natl. Acad. Sci. USA 2010, 107:2183-2188.
76. Godlewski J., Nowicki M.O., Bronisz A., Williams S., Otsuki A., Nuovo G., Raychaudhury A., Newton H.B., Chiocca E.A., Lawler S. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 2008, 68:9125-9130.
77. Gaur A., Jewell D.A., Liang Y., Ridzon D., Moore J.H., Chen C., Ambros V.R., Israel M.A. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007, 67:2456-2468.
78. Pang J.C., Kwok W.K., Chen Z., Ng H.K. Oncogenic role of microRNAs in brain tumors. Acta Neuropathol. 2009, 117:599-611.
79. Li Y., Guessous F., Zhang Y., diPierro C., Kefas B., Johnson E., Marcinkiewicz L., Jiang J., Yang Y., Schmittgen T.D., Lopes B., Schiff D., Purow B., Abounader R. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009, 69:7569-7576.
80. Mei J., Bachoo R., Zhang C.L. MicroRNA-146a inhibits glioma development by targeting Notch1. Mol. Cell Biol. 2011, 31:3584-3592.
81. Kefas B., Godlewski J., Comeau L., Li Y., Abounader R., Hawkinson M., Lee J., Fine H., Chiocca E.A., Lawler S., Purow B. MicroRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008, 68:3566-3572.
82. T. Papagiannakopoulos, D. Friedmann-Morvinski, P. Neveu, J.C. Dugas, R.M. Gill, E. Huillard, C. Liu, H. Zong, D.H. Rowitch, B.A. Barres, I.M. Verma, and K.S. Kosik, Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases, Oncogene (2011).
83. Zhang Q.Q., Xu H., Huang M.B., Ma L.M., Huang Q.J., Yao Q., Zhou H., Qu L.H. MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neuro-Oncology 2012, 14:278-287.
84. Gabriely G., Yi M., Narayan R.S., Niers J.M., Wurdinger T., Imitola J., Ligon K.L., Kesari S., Esau C., Stephens R.M., Tannous B.A., Krichevsky A.M. Human glioma growth is controlled by microRNA-10b. Cancer Res. 2011, 71:3563-3572.
85. Gabriely G., Wurdinger T., Kesari S., Esau C.C., Burchard J., Linsley P.S., Krichevsky A.M. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell Biol. 2008, 28:5369-5380.
86. Huse J.T., Brennan C., Hambardzumyan D., Wee B., Pena J., Rouhanifard S.H., Sohn-Lee C., le S.C., Agami R., Tuschl T., Holland E.C. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 2009, 23:1327-1337.
87. * promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-kappaB/IkappaBalpha negative feedback loop. J. Clin. Invest. 2012, 122:33-47.
88. Quintavalle C., Garofalo M., Zanca C., Romano G., Iaboni M., del Basso De C.M., Martinez-Montero J.C., Incoronato M., Nuovo G., Croce C.M., Condorelli G. MiR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPmu. Oncogene 2012, 31:858-868.
89. Zhang C.Z., Zhang J.X., Zhang A.L., Shi Z.D., Han L., Jia Z.F., Yang W.D., Wang G.X., Jiang T., You Y.P., Pu P.Y., Cheng J.Q., Kang C.S. MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol. Cancer 2010, 9:229.
90. Gillies J.K., Lorimer I.A. Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 2007, 6:2005-2009.
91. Saito Y., Liang G., Egger G., Friedman J.M., Chuang J.C., Coetzee G.A., Jones P.A. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer cell 2006, 9:435-443.
92. Lujambio A., Ropero S., Ballestar E., Fraga M.F., Cerrato C., Setien F., Casado S., Suarez-Gauthier A., Sanchez-Cespedes M., Git A., Spiteri I., Das P.P., Caldas C., Miska E., Esteller M. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007, 67:1424-1429.
93. Garzon R., Liu S., Fabbri M., Liu Z., Heaphy C.E., Callegari E., Schwind S., Pang J., Yu J., Muthusamy N., Havelange V., Volinia S., Blum W., Rush L.J., Perrotti D., Andreeff M., Bloomfield C.D., Byrd J.C., Chan K., Wu L.C., Croce C.M., Marcucci G. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009, 113:6411-6418.
94. Noonan E.J., Place R.F., Pookot D., Basak S., Whitson J.M., Hirata H., Giardina C., Dahiya R. MiR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009, 28:1714-1724.
95. Zhang Z., Tang H., Wang Z., Zhang B., Liu W., Lu H., Xiao L., Liu X., Wang R., Li X., Wu M., Li G. MiR-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma. Mol. Cancer 2011, 10:124.
96. Varambally S., Cao Q., Mani R.S., Shankar S., Wang X., Ateeq B., Laxman B., Cao X., Jing X., Ramnarayanan K., Brenner J.C., Yu J., Kim J.H., Han B., Tan P., Kumar-Sinha C., Lonigro R.J., Palanisamy N., Maher C.A., Chinnaiyan A.M. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322:1695-1699.
97. Smits M., Nilsson J., Mir S.E., van der Stoop P.M., Hulleman E., Niers J.M., de Witt Hamer P.C., Marquez V.E., Cloos J., Krichevsky A.M., Noske D.P., Tannous B.A., Wurdinger T. MiR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 2010, 1:710-720.
98. Berdasco M., Ropero S., Setien F., Fraga M.F., Lapunzina P., Losson R., Alaminos M., Cheung N.K., Rahman N., Esteller M. Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc. Natl. Acad. Sci. USA 2009, 106:21830-21835.
99. Wang M., Xie H., Stellpflug W., Rajaram V., Bonaldo M.F., Goldman S., Tomita T., Soares M.B. BTECH: a platform to integrate genomic, transcriptomic and epigenomic alterations in brain tumors. Neuroinformatics 2011, 9:59-67.
100. Esteller M. Cancer epigenetics for the 21st century: what's next?. Genes Cancer 2011, 2:604-606.
101. Malzkorn B., Wolter M., Riemenschneider M.J., Reifenberger G. Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets. Brain Pathol. 2011, 21:619-632.
102. Riemenschneider M.J., Jeuken J.W., Wesseling P., Reifenberger G. Molecular diagnostics of gliomas: state of the art. Acta Neuropathol. 2010, 120:567-584.
103. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12:1247-1252.
104. Kelly T.K., De Carvalho D.D., Jones P.A. Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 2010, 28:1069-1078.
105. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27:5459-5468.
106. Chinnaiyan P., Vallabhaneni G., Armstrong E., Huang S.M., Harari P.M. Modulation of radiation response by histone deacetylase inhibition. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62:223-229.
107. Yin D., Ong J.M., Hu J., Desmond J.C., Kawamata N., Konda B.M., Black K.L., Koeffler H.P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin. Cancer Res. 2007, 13:1045-1052.
108. Eyupoglu I.Y., Hahnen E., Buslei R., Siebzehnrubl F.A., Savaskan N.E., Luders M., Trankle C., Wick W., Weller M., Fahlbusch R., Blumcke I. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J. Neurochem. 2005, 93:992-999.
109. Entin-Meer M., Yang X., VandenBerg S.R., Lamborn K.R., Nudelman A., Rephaeli A., Haas-Kogan D.A. In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro-Oncology 2007, 9:82-88.
110. Drappatz J., Lee E.Q., Hammond S., Grimm S.A., Norden A.D., Beroukhim R., Gerard M., Schiff D., Chi A.S., Batchelor T.T., Doherty L.M., Ciampa A.S., Lafrankie D.C., Ruland S., Snodgrass S.M., Raizer J.J., Wen P.Y. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J. Neurooncol. 2012, 107:133-138.
111. Masoudi A., Elopre M., Amini E., Nagel M.E., Ater J.L., Gopalakrishnan V., Wolff J.E. Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res. 2008, 28:2437-2442.
112. Galanis E., Jaeckle K.A., Maurer M.J., Reid J.M., Ames M.M., Hardwick J.S., Reilly J.F., Loboda A., Nebozhyn M., Fantin V.R., Richon V.M., Scheithauer B., Giannini C., Flynn P.J., Moore D.F., Zwiebel J., Buckner J.C. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J. Clin. Oncol. 2009, 27:2052-2058.
113. Weller M., Gorlia T., Cairncross J.G., van den Bent M.J., Mason W., Belanger K., Brandes A.A., Bogdahn U., Macdonald D.R., Forsyth P., Rossetti A.O., Lacombe D., Mirimanoff R.O., Vecht C.J., Stupp R. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011, 77:1156-1164.
114. Wang K., Zhang S., Marzolf B., Troisch P., Brightman A., Hu Z., Hood L.E., Galas D.J. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl. Acad. Sci. USA 2009, 106:4402-4407.
115. Hunter M.P., Ismail N., Zhang X., Aguda B.D., Lee E.J., Yu L., Xiao T., Schafer J., Lee M.L., Schmittgen T.D., Nana-Sinkam S.P., Jarjoura D., Marsh C.B. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008, 3:e3694.
116. Iorio M.V., Croce C.M. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 2009, 27:5848-5856.
117. Roth P., Wischhusen J., Happold C., Chandran P.A., Hofer S., Eisele G., Weller M., Keller A. A specific miRNA signature in the peripheral blood of glioblastoma patients. J. Neurochem. 2011, 118:449-457.
118. Baraniskin A., Kuhnhenn J., Schlegel U., Maghnouj A., Zollner H., Schmiegel W., Hahn S., Schroers R. Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro-Oncology 2012, 14:29-33.
119. Petri A., Lindow M., Kauppinen S. MicroRNA silencing in primates: towards development of novel therapeutics. Cancer Res. 2009, 69:393-395.
120. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., Persson R., Lindow M., Munk M.E., Kauppinen S., Orum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.
121. R.E. van, W.S. Marshall, E.N. Olson, Toward microRNA-based therapeutics for heart disease: the sense in antisense, Circ. Res. 103 (2008) 919-928.
122. Elmen J., Lindow M., Schutz S., Lawrence M., Petri A., Obad S., Lindholm M., Hedtjarn M., Hansen H.F., Berger U., Gullans S., Kearney P., Sarnow P., Straarup E.M., Kauppinen S. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452:896-899.
123. Weiler J., Hunziker J., Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?. Gene Ther. 2006, 13:496-502.
124. Ebert M.S., Neilson J.R., Sharp P.A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 2007, 4:721-726.
125. Castanotto D., Rossi J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009, 457:426-433.
126. Cairncross G., Berkey B., Shaw E., Jenkins R., Scheithauer B., Brachman D., Buckner J., Fink K., Souhami L., Laperierre N., Mehta M., Curran W. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J. Clin. Oncol. 2006, 24:2707-2714.
127. van den Bent M.J., Carpentier A.F., Brandes A.A., Sanson M., Taphoorn M.J., Bernsen H.J., Frenay M., Tijssen C.C., Grisold W., Sipos L., Haaxma-Reiche H., Kros J.M., van Kouwenhoven M.C., Vecht C.J., Allgeier A., Lacombe D., Gorlia T. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J. Clin. Oncol. 2006, 24:2715-2722.
128. Ohgaki H., Kleihues P. Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol. 2011, 28:177-183.
129. Kim Y.H., Nobusawa S., Mittelbronn M., Paulus W., Brokinkel B., Keyvani K., Sure U., Wrede K., Nakazato Y., Tanaka Y., Vital A., Mariani L., Stawski R., Watanabe T., De G.U., Kleihues P., Ohgaki H. Molecular classification of low-grade diffuse gliomas. Am. J. Pathol. 2010, 177:2708-2714.
130. Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., Reulen H.J. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006, 7:392-401.
131. Thon N., Eigenbrod S., Grasbon-Frodl E.M., Ruiter M., Mehrkens J.H., Kreth S., Tonn J.C., Kretzschmar H.A., Kreth F.W. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas. J. Neuropathol. Exp. Neurol. 2009, 68:1219-1228.
132. Thon N., Eigenbrod S., Grasbon-Frodl E.M., Lutz J., Kreth S., Popperl G., Belka C., Kretzschmar H.A., Tonn J.C., Kreth F.W. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. J. Neurol. Neurosurg. Psychiatry 2011, 82:441-446.
133. Mardis E.R. A decade's perspective on DNA sequencing technology. Nature 2011, 470:198-203.
134. E. Meaburn, R. Schulz, Next generation sequencing in epigenetics: insights and challenges, Semin. Cell Dev. Biol. (2011.
135. Riddick G., Fine H.A. Integration and analysis of genome-scale data from gliomas. Nat. Rev. Neurol. 2011, 7:439-450.